What's Happening?
The U.S. Food and Drug Administration (FDA) has recently approved several new cancer treatments and expanded indications for existing therapies. On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus
Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This approval expands the prior indication to include patients with high-grade papillary-only tumors, based on the efficacy demonstrated in the QUILT-3.032 trial. Additionally, on October 16, 2026, the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H) solid tumors. This converts a previous accelerated approval and refines the TMB-H definition to ≥ 13 mutations/megabase. Furthermore, on October 19, 2026, the PD-1 inhibitor dostarlimab (Jemperli) received accelerated approval for adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR), following evaluation in the AZUR-1 trial.
Why It's Important?
These FDA approvals are significant for patients in the U.S. facing advanced bladder and rectal cancers, as well as other solid tumors with high mutational burden. The expanded indication for nogapendekin alfa inbakicept-pmln offers a new treatment option for a broader group of NMIBC patients, potentially improving outcomes for those with high-grade papillary-only tumors who previously had limited choices. The traditional approval for pembrolizumab, a widely used immunotherapy, solidifies its role in treating TMB-H solid tumors, providing a clearer definition for patient eligibility and ensuring continued access to this therapy. The accelerated approval of dostarlimab for locally advanced rectal cancer represents a crucial advancement, offering a novel treatment approach for patients with MSI-H/dMMR tumors, who often have a poor prognosis with conventional therapies. These developments underscore the ongoing progress in oncology, bringing hope for improved survival and quality of life for many cancer patients.
What's Next?
Following these approvals, healthcare providers will integrate these new and expanded treatment options into their clinical practices for eligible patients. For nogapendekin alfa inbakicept-pmln, clinicians will now consider its use for patients with high-grade papillary-only NMIBC, in addition to those with carcinoma in situ. The refined definition for TMB-H in pembrolizumab's indication will guide more precise patient selection for this immunotherapy. For dostarlimab, as an accelerated approval, further studies may be required to confirm its clinical benefit and convert it to traditional approval. The FDA is also working to finalize guidance for BCG-unresponsive NMIBC, which will further inform drug development and treatment strategies in this area. These approvals are expected to influence treatment guidelines and potentially lead to better patient outcomes in these challenging cancer types.
Beyond the Headlines
The approvals highlight a broader trend in oncology towards personalized medicine, where treatments are tailored based on specific tumor characteristics like TMB-H, MSI-H, or dMMR. This shift moves beyond traditional broad-spectrum chemotherapy, offering more targeted and potentially more effective therapies with fewer side effects for specific patient populations. The use of combination therapies, such as nogapendekin alfa inbakicept-pmln with BCG, also reflects an evolving understanding of cancer biology and the potential for synergistic effects between different treatment modalities. Furthermore, the FDA's use of programs like Project Orbis and Real-Time Oncology Review demonstrates an ongoing effort to expedite the availability of promising cancer treatments to patients, often through international collaboration, which could set precedents for future drug approvals and regulatory processes.
